Recent Developments in Cancer Biomarkers for Diagnosis and Prognosis
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".
Deadline for manuscript submissions: 25 January 2025 | Viewed by 210
Special Issue Editor
Interests: anti-cancer mechanisms of organo-selenium compounds; cancer biomarkers; chemoprevention; cancer therapy; dietary manipulations; inflammation; systems biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The biological molecules reflecting the state of initiation and progression in cancer are deemed important biomarkers. These molecules can be measured in tissues, plasma serum saliva, and other biological fluids. Cancer biomarkers are useful not only for early detection but also for monitoring disease progression and treatments. Measuring one biomarker may not be sufficient for all cancer types, and some cancers require a group of biomarkers for accurate diagnosis. These biomarkers could be a combination of tissue and secretory factors. This Special Issue welcomes research articles addressing recent research on experimental, pre-clinical, and clinical cancer biomarkers for diagnosis and prognosis, with a special focus on approaches for discovering novel cancer biomarkers. Biomarkers can include proteins, nucleic acids, metabolites, and more.
Dr. Raghu Sinha
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biomarkers
- diagnosis
- prognosis
- therapy response biomarkers
- miRNA, RNA, DNA, and proteins
- cell-free biomarkers
- saliva, serum, and plasma
- inflammation
- metabolites
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
